New drug combo aims to shrink tough pancreatic tumors before surgery
NCT ID NCT06821997
Summary
This study is testing a specific combination of four chemotherapy drugs given to patients before surgery for a type of pancreatic cancer that is difficult to remove. The goal is to see if shrinking the tumor first makes surgery more successful and lowers the chance of the cancer coming back later. About 20 adults with this specific stage of pancreatic cancer will receive the drug treatment, followed by surgery and possibly more chemotherapy afterward.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.